Replies to post #178737 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

This whole thread, including my posts, is becoming (or always was) in IMO completely irrelevant to $AVXL. Mainly because we can't buy shares in United Neuroscience, at least not yet.

Except for maybe interesting for a couple of reasons from United Neuroscience About:

*DR. JEFFREY CUMMINGS, except bio link is not working, is also SAB member of Anavex.
*Paul Maruff appears in several Anavex posters e.g. this one

I guess if we have confidence in those two names for $AVXL, maybe United Neuroscience is also worth a look?

The science behind the vaccine does look interesting and quiet different from monoclonal antibodies. Still the big issue is that it isn't at all clear that removing amyloid plaque will stop or reverse AD. Amyloid plaque is more likely a pathology of AD and not a cause, in fact some scientists now believe that the amyloid plaque is a protective response to an upstream issue.

Finally, the recent UB-111 P2 trial was in 43 patients with three arms: two treatment arm and a placebo arm. The positive results were not stat sig. In comparison the A2-73 treated 32 patients and was not placebo controlled, but met all endpoints. I would argue that the A2-73 adaptive crossover trial design yielded far more information about A2-73 than a similar size 3 arm placebo controlled design would.

Aside from all that and more importantly, IMO, is that A2-73 addresses an upstream mitochondrial dysfunction that also in turn stops the protein misfolding that leads to plaque and tangles.